Key clinical takeaways:  

• Metastatic breast cancer (mBC) is a complex, heterogeneous disease requiring multidisciplinary collaboration. Pathologists are central to this process to ensure accurate interpretation and optimal patient management   

• Incorporating HER2-low and HER2-ultralow categories in biomarker testing is critical for mBC due to the demonstrated efficacy of HER2-targeted antibody-drug conjugates, such as trastuzumab deruxtecan, in these patient subsets, expanding therapeutic options beyond traditional HER2-positive cases   

• High-quality pre-analytical handling and nuanced interpretation are essential for accurate HER2 classification, particularly for HER2-low and –ultralow disease. Small errors in testing or interpretation can lead to missed treatment opportunities. 

This is the full video. Watch the shorter highlights video here: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=0 

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying one-page snapshot: https://cor2ed.com/precision-oncology-connect/programmes/biomarker-testing-breast-cancer/?media=2 

Follow us on social media: 

LinkedIn: https://linkedin.com/company/ntrk-connect 

X: https://x.com/PresOnc_Connect 

This content is intended for healthcare professionals only.  

This video is supported by an Independent Education Grant from Daiichi Sankyo. 

This video is developed by cor2ed.com 

Published on March 2026. 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this video podcast moderated by the Oncology Brothers, Dr Komal Jhaveri provides a practical overview of how this shift beyond a binary HER2 model translates into everyday clinical practice.

The experts explore:

• Key efficacy data from DESTINY-Breast04 and DESTINY-Breast06, and their impact on the HER2 treatment framework
• The clinical relevance of HER2-low and HER2-ultralow categories, and review the CAP reporting template
• When and why to perform re-biopsy to detect changes in HER2 expression over time
• Best practices for monitoring and managing T-DXd–related adverse events, including nausea, vomiting, fatigue and ILD/pneumonitis

Watch now to deepen your understanding of HER2-low and HER2-ultralow classification, refine how and when you test, and appreciate the impact on therapeutic decision-making in mBC.

Clinical takeaways

• DESTINY-Breast04 and DESTINY-Breast-06 established T-DXd as an effective option for HER2-low and HER2-ultralow mBC, improving PFS and OS and showing that even minimal HER2 expression can identify patients who benefit from T-DXd
• Current CAP reporting template separates HER2-low (IHC 1+ or 2+/ISH–) and HER2-ultralow (IHC 0 with faint or incomplete membrane staining in ≤10% of tumour cells) from true HER2-0, creating treatment-defining strata for HER2-targeted ADCs such as T-DXd
• Because HER2 expression is dynamic between primary and metastatic sites and over time, re-biopsy at progression, particularly in tumours previously scored as HER2-0, should be considered to identify new candidates for T-DXd
• T-DXd delivers substantial antitumour activity, but treatment-related adverse events, including nausea, vomiting, fatigue, alopecia and, in particular, ILD/pneumonitis, require careful and proactive management. Clinicians should apply structured supportive care and early, vigilant monitoring to ensure safe and sustained treatment

This is the full video. Watch the shorter highlights video here: https://youtu.be/3xepcF70Ljw

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/breastcancerconnect/

X: https://x.com/BreastCaConnect

This content is intended for healthcare professionals only.

This programme is supported by an Independent Education Grant from AstraZeneca.

This podcast is developed by cor2ed.com

Published December 2025

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

They clarify the crucial differences between NETs and NECs, explain why accurate classification and rapid treatment are essential, and highlight current and emerging therapeutic approaches, including DLL3-targeted therapies.  

Through both HCP and patient-centred perspectives, the conversation addresses real-world challenges, the importance of support networks, and the growing sense of hope for people affected by this difficult disease. 

Key clinical takeaways:  

• Unlike NETs, EP-NECs are poorly differentiated, high-grade, aggressive, and fast-growing cancers, with a need for more effective treatments

• While there remains a medical need for effective treatment of EP-NECs, clinical studies with DLL3-targeted agents show promise 

• Accessing a support network can provide emotional reinforcement and information for patients and their care partners 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/net-connect/programmes/ep-nec-diagnosis-treatment-support/?media=0 

Or watch on YouTube: https://youtu.be/nfng2s3jSw8 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

X:https://x.com/net_connectinfo 

This podcast is supported by an Independent Education Grant from Boehringer Ingelheim.

This podcast is developed by cor2ed.com 

Published in November 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this podcast moderated by the Oncology Brothers, Drs Rohit and Rahul Gosain are joined by medical oncologist Dr Heloisa Soares and nuclear medicine physician Prof. Ken Herrmann to explore the evolving role of targeted radioligand therapy in NETs. 

As the conversation unfolds, the experts discuss evidence from recent studies, including the COMPETE trial, share practical insights on multidisciplinary decision-making, and highlight future directions such as the potential for first-line treatment with radioligand therapy. 

Key clinical takeaways:  

• Pair the right patient with the right treatment using an understanding of the key clinical studies 

• The role of PRRT as a very effective 2nd-line treatment was consolidated by the COMPETE study data  

• The best outcomes are achieved through multi-disciplinary collaborations that include the patient 

Listen to the audio version of this conversation on Spotify, Apple, or on the COR2ED website, where you can also download the accompanying transcript and infographic: https://cor2ed.com/net-connect/programmes/targeted-radiopharmaceutical-treatment-nets/?media=0

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect/?viewAsMember=true  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

This podcast is supported by an Independent Education Grant from ITM.  

This podcast is developed by cor2ed.com 

Published September 2025 

This video includes the highlights from a video podcast where medical oncologists Prof Shubham Pant and Prof Efrat Dotan discuss how to choose and optimise the different chemotherapeutic options at first and second line. 

Key clinical takeaways: 

• mPDAC is notoriously aggressive with a poor prognosis. Patients are generally diagnosed with advanced-stage disease and require treatment with chemotherapy as soon as possible
• Frontline regimens should be individualised based on performance status, comorbidities, and risk of neuropathy; FOLFIRINOX, NALIRIFOX, and gemcitabine/nab-paclitaxel all offer survival benefit with distinct toxicity profiles
• Choice of 2nd line treatment should be guided by prior regimen and patient fitness
• Dose modification and alternative scheduling are standard in real-world practice and are used to maintain dose intensity while improving tolerability and reducing adverse events

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/gi-connect/programmes/tackling-mpdac/?media=0 

Or watch on YouTube: https://youtu.be/8YxRnjOYUv4 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/giconnect 

X: https://x.com/giconnectInfo 

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Ipsen USA. 

This podcast is developed by cor2ed.com 

Published May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.

As a patient advocate as well as a patient herself, Debra brings a wealth of experience and depth of insight into the discussion with Dr Sabari.   

Dr Sabari shares his clinical knowledge regarding diagnosis, biomarker testing and treatment of such alterations, together with his own first-hand experience of treating and empowerig patients like Debra in their own treatment journey. 

What does the patient pathway look like from both perspectives?  What are the needs of Medical Oncologists and patients when navigating the treatment journey?  What do patients need from their oncologists?  What do oncologists think their patients need from them?  Are these needs matched by the support currently available?   

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/understanding-rare-nsclc-mutations/?media=0 

Or watch on YouTube: https://www.youtube.com/watch?v=Z57cUtQx1BE&t 

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Boehringer Ingelheim. 

This podcast is developed by cor2ed.com 

Published on May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

This is the second episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

In this episode Drs Isabel Preeshagul and Eric Singhi provide the benefit of their experience when discussing how to approach different treatment scenarios in HER2-mutant NSCLC. 

The conversation unfolds to cover; 

• How to distinguish HER2 alterations from other alterations on biomarker reports 

• The latest efficacy and safety data of currently approved and emerging treatments for HER2-altered NSCLC  

• The potential CNS activity of these treatments in patients with HER2-mutated NSCLC 

• How the treatment pathway may look in the near future 

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-2/

Or watch on YouTube: https://youtu.be/E8-3GDyJT9Y

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published on May 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in NSCLC, hosted by the Oncology Brothers, Drs Rohit and Rahul Gosain.   

What makes this conversation so interesting, is that you can gather insights from both the Medical Oncologist perspective with Dr Devika Das, and pathology perspective from Prof. Lopéz-Ríos. 

In this episode the discussion focuses identifying HER2-directed NSLC, considering mutations, overexpression and amplifications, whilst not forgetting how best practice in identification of HER2 alterations may be translated in the community setting. 

Listen to different expert perspectives on 

• The different HER2 alterations and prevalence in NSCLC 

• Which technique to identify which HER2 alteration 

• HER2-targeted treatments, both approved and in development 

You can also watch a video of the experts in conversation and download the transcript on our website: https://cor2ed.com/lung-connect/programmes/her2-diagnostic-treatment-nsclc-1/?media=1 

Or watch on YouTube: https://youtu.be/3vMCzR1jqbI 

Follow LUNG CONNECT on social media: 

X – https://x.com/lung_connect  

LinkedIn – https://www.linkedin.com/company/lungconnect/  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published on April 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Key topics include 

• Identifying tumors that remain endocrine-sensitive despite acquired resistance to previous ET 

• Clinical implications of the EMERALD subgroup analyses 

• Review of elacestrant's safety profile 

Clinical takeaways 

• Duration of prior ET + CDK4/6i ≥12 months was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC endocrine monotherapy in patients with ESR1-mut, ER+/HER2– metastatic breast cancer 

• The PFS benefit associated with elacestrant was consistent across clinically relevant subgroups evaluated, including patients with bone metastases, liver and/or lung metastases, n<3 or ≥3 metastatic sites or tumors with PIK3CA-mut, TP53-mut, HER2-low tumor expression, or ESR1-mut variants D538G or Y537S/N 

• Safety analyses demonstrated that elacestrant had a manageable safety profile similar to other ETs and without evidence of the toxicities associated with other drug classes, such as CDK4/6i and PI3K/AKT/mTOR inhibitors 

• These data support current guidelines that recommend routine testing for the emergence of ESR1-mut in ctDNA at each disease progression 

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only. 

This video was developed by https://cor2ed.com/ 

Published March 2025 

Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.  

Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.  

Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes. 

Key clinical takeaways: 

• Molecular testing, especially for biomarkers like ESR1 and PI3 kinase, is a critical component in guiding treatment decisions, particularly in second-line therapy for HR+ HER2- metastatic breast cancer. 

• Liquid biopsy is a valuable tool for ongoing monitoring of metastasis and detecting mutations like ESR1 during disease progression, but tissue biopsies may yield more reliable results for certain mutations like PI3 kinase alterations present early in cancer development. 

• Testing for a broad range of mutations, such as PI3 kinase, AKT, PTEN, ESR1, MSI, and NTRK, allows for the identification of actionable mutations and eligibility for newer targeted therapies, especially in second and third-line treatments. 

• Clinicians must be familiar with the specifics of the assays used to test for mutations, as different methods and testing conditions can impact results. 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0

Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/ntrk-connect/  

X: https://x.com/PresOnc_Connect  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific. 

This podcast is developed by cor2ed.com 

Published March 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Key clinical takeaways:  

• MMR status should be tested in all patients at diagnosis and upon disease progression to guide personalised treatment decisions  

• ICI and ChT combination, including with maintenance olaparib, demonstrates benefits in patients with non-dMMR advanced/recurrent endometrial cancer, with greater efficacy observed in dMMR populations 

• Lenvatinib plus pembrolizumab is a viable option not only as 2nd line therapy but also as 1st line treatment for patients with non-dMMR advanced/recurrent endometrial cancer who have progressed after prior systemic therapy in any setting 

• Shared decision-making, supported by patient education, is essential for optimising treatment outcomes  

The treatment landscape for advanced and recurrent endometrial cancer (EC) is evolving, with molecular classification playing a key role in guiding decisions. In this podcast, Prof. Xavier Matias-Guiu (Pathologist) and Dr Jurjees Hasan (Medical Oncologist) discuss the latest advancements in personalised treatment approaches for EC. 

Key topics include: 

• The role of molecular classification in guiding treatment selection and testing strategies 

• Treatment options for patients with pMMR status 

• Effective patient communication for shared decision-making 

Tune in for expert insights and practical guidance to optimise treatment strategies in advanced and recurrent EC 

You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/obstetrics-gynecology-connect/programmes/endometrial-cancer-molecular-classification-treatment-decisions/ 

Or watch on YouTube: https://youtu.be/KvYIB7PBpyQ 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/ob-gyn-connect/?viewAsMember=true  

X: https://x.com/OBGynConnect  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this podcast. 

This podcast is developed by cor2ed.com 

Published February 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this final episode of the four-part series on hepatocellular carcinoma (HCC), hosted by the Oncology Brothers Drs Rohit and Rahul Gosain, the discussion focuses on the evolving role of immunotherapy (IO) in intermediate HCC. The episode explores multimodal approaches that combine IO and IO-based therapies with loco-regional treatments and highlights the essential role of a multidisciplinary care team.  

Joined by Drs Nina Sanford (radiation oncologist), Mark Yarchoan (medical oncologist) and Ed Kim (interventional radiologist), the experts provide a brief overview of current treatment options for intermediate HCC, addressing its heterogeneity and standard treatment pathways. They delve into the latest clinical trial data (EMERALD-1, LEAP-012) on combining IO with loco-regional therapies, discussing clinical implications. The conversation also underscores the importance of effective collaboration within the multidisciplinary team for delivering optimal patient care. The episode concludes with future perspectives in the field and key clinical takeaways on integrating IO with loco-regional therapy and the significance of multidisciplinary care in managing HCC. 

Key clinical takeaways:  

• IO and IO-based treatments are moving earlier in the treatment paradigm for patients with intermediate HCC. Earlier integration of these therapies aims to achieve improved systemic control, allowing loco-regional therapy to target oligoprogression, residual lesions or reduce tumour burden 

• Emerging data supports combining systemic and loco-regional therapies for patients with intermediate HCC. EMERALD-1 and LEAP-012 show promising PFS data using IO-based combination regimens like durvalumab + bevacizumab or pembrolizumab + lenvatinib alongside TACE. Long-term OS data are awaited 

• Effective communication and coordinated care among specialists, such as medical oncologists, radiation oncologists, hepatologists, and interventional radiologists, are essential to developing optimal treatment strategies for patients with intermediate HCC 

You can also watch a video of the experts in conversation and download the accompanying slides and transcript on our website: https://cor2ed.com/hcc-connect/programmes/intermediate-hcc-the-evolving-role-of-io/ 

Or watch on YouTube: https://www.youtube.com/watch?v=3voWa0U96lE 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect/

X https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. 

This podcast is developed by cor2ed.com 

Published on January 2025 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Key topics include: 

• An overview of the available treatment options for this heterogeneous patient population with intermediate HCC 

• A deep dive into loco-regional therapies, including TACE, TARE (Y-90), and SBRT 

• Exploring the role of systemic treatments in patients with intermediate HCC and the use of multimodal treatment approaches, combining loco-regional treatment options with systemic treatments 

• The importance of the multidisciplinary care team for the treatment of intermediate HCC 

Key clinical takeaways:  

• Defined by guidelines, treatment options for patients with intermediate HCC include liver transplantation, loco-regional therapies, and systemic therapy. Treatment selection depends not only on tumour burden and liver function, but also on practical considerations in clinical practice 

• Systemic therapies are being evaluated earlier in the disease course, particularly for intermediate HCC, either as standalone treatments or in combination with loco-regional therapies 

• Ongoing clinical trials, such as REPLACE and ABC-HCC, aim to clarify the role of systemic therapies in intermediate HCC as standalone options, while others, like EMERALD-1 and LEAP-012, focus on their use in combination with loco-regional approaches 

• Adverse events require identification of the specific adverse events profile. Regardless of origin (systemic or loco-regional), complications must be resolved to maintain treatment efficacy and ensure patient safety 

• Optimal care for intermediate HCC relies on a multi-disciplinary team, including hepatologists, interventional radiologists, radiation oncologists, surgeons, and medical oncologists 

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/  

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published January 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

Topics include: 

• 2nd line options for advanced HCC after 1st line TKIs and IO-based therapies 

• Sequencing strategies and clinical practice approaches 

• Key data supporting 2nd line decisions 

• Factors to consider when transitioning to 2nd line therapy 

Key clinical takeaways:  

• Prospective Phase 3 data on 2nd line options in advanced HCC, particularly after immunotherapy, is limited, highlighting the need for further evidence to guide optimal treatment decisions 

• When switching to 2nd line therapy, it is essential to evaluate all the available treatment options to ensure the optimal choice for each patient, considering efficacy, tolerability, liver function, and quality of life. 

• Switching to 2nd line therapy should be considered in cases of clear disease progression, such as the appearance of new lesions outside the liver. Best supportive care should also be considered 

• Managing side effects of 2nd line treatments (e.g. hypertension, skin toxicity, proteinuria) is critical for maintaining quality of life and providing optimal disease management 

• Effective management requires a multidisciplinary team effort, including oncologists, hepatologists, interventional radiologists, and other specialists to optimise outcomes and proactively manage symptoms like hepatic decompensation 

Prefer to watch the experts in conversation? Go to the video on our website: https://cor2ed.com/hcc-connect/programmes/advanced-hcc-treatment-selection/  

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. 

This podcast is developed by cor2ed.com 

Published December 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

In this educational podcast episode, experts Prof. David Planchard and Dr Federico Cappuzzo discuss the significance of BRAF mutations in metastatic non-small cell lung cancer (NSCLC), the testing strategies and first- and second-line treatment options for these patients.  

The discussion focuses on which BRAF mutations to test for and when in the patient journey to test, before moving on to consider if NGS broad panel testing should be applied routinely for patients.  Various treatments are considered, along with which decision criteria come into play when selecting a particular treatment.  

The experts also discuss how to treat patients who have co-mutations detected during testing. 

This is an informative podcast that culminates in some interesting key messages from two well-recognised Experts in the field of NSCLC. 

Key clinical takeaways:  

• Test all patients irrespective of histology and smoking history 

• Test upfront so that more efficacious agents can be used earlier in the patient journey 

• Next-generation sequencing is the gold-standard for testing wherever possible to ensure various targetable alterations are not missed 

• There are effective BRAF + MEK inhibitor combination treatments available to treat our BRAFv600E-mutant metastatic NSCLC patients which have manageable safety profiles 

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/UZPBUAFOwcY

Download the trasncript and find out more about this programme and the featured experts here: https://cor2ed.com/lung-connect/programmes/testing-treatment-braf-mutant-metastatic-nsclc/

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/lungconnect/  

X: https://x.com/lung_connect  

This content is intended for healthcare professionals outside of the UK & ROI only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

This podcast is developed by https://cor2ed.com/ 

Published November 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

• Current first-line systemic treatment options for uHCC 
• Efficacy and safety of IO and IO combinations including practical aspects of identifying and managing immune-mediated AEs 
• How to select between the two first-line IO-based treatment options based on clinical factors and practical considerations  

Key clinical takeaways:

• Two first-line IO and IO-based combinations are approved for patients with unresectable hepatocellular carcinoma (HCC), with ongoing advancements shaping the treatment landscape 
• Clinical trials in newly diagnosed unresectable HCC patients have validated the effectiveness of IO plus anti-VEGF (atezolizumab + bevacizumab, IMbrave150) and dual IO (tremelimumab + durvalumab, HIMALAYA) approaches, establishing the proof of principle for these strategies 
• Landmark analysis is critical in IO-based treatments due to the delayed and continued separation of survival curves. Notably, the STRIDE regimen ( single tremelimumab regular interval durvalumab) shows one in five patients achieving five-year survival in long-term follow-up 
• IO and IO-based regimens for unresectable HCC are generally well-tolerated, with immune-related adverse effects manageable using steroids when necessary. 
• In clinical practice, treatment choice should be individualized, taking into account factors such as potential side effects and logistical considerations, including the frequency of hospital visits 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/hcc-connect  

X: https://x.com/hccconnectinfo  

This content is intended for healthcare professionals only.  

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. AstraZeneca has provided a sponsorship grant towards this independent programme. 

This podcast is developed by cor2ed.com 

Published on November 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

They consider the prevalence and types of BRAF mutations in CRC patients and highlight the poor prognosis for these patients. The experts also cover the optimal time and methods for testing for BRAF mutations, as well as the targeted therapies currently available for BRAF-mutated CRC.  

Several key trials are discussed, including the BEACON trial which resulted in encorafenib plus cetuximab being the standard of care in the second-line setting for patients with BRAF mutated CRC.  

The discussion also looks at future studies including the BREAKWATER trial, which will provide important information about encorafenib plus cetuximab in the first-line for these patients, as well as the SEAMARK trial which will show the effects of adding immunotherapy to this combination.   

Key clinical takeaways: 

• BRAF mutations occur in around 10% of colorectal cancer patients and patients harbouring these have aggressive disease and a poor prognosis 

• Targeted therapies are available for BRAF-mutated CRC so it is important to test patients early in their disease preferably with next-generation sequencing 

• Encorafenib plus cetuximab are established as the standard of care in the second-line setting for BRAF-mutated CRC 

• Doublet chemotherapy plus anti-VEGF is currently the preferred treatment in the first-line. The BREAKWATER trial will determine whether the combination of encorafenib plus cetuximab is a suitable first-line treatment option 

Would you prefer to watch the experts in conversation? This podcast episode is also available in video format, here: https://youtu.be/Pp7oAI9JW4A 

Download the transcript and find out more about this programme and the featured experts here: https://cor2ed.com/gi-connect/programmes/braf-mutated-crc-testing-treatment/ 

Follow us on social media: 

LinkedIn: https://www.linkedin.com/company/giconnect   

X: https://x.com/giconnectInfo  

This content is intended for healthcare professionals outside of the UK & ROI only.

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts.

This podcast was developed by https://cor2ed.com/  

Published November 2024 

Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released. 

The speakers discuss different treatment settings, including home vs hospital-based injections, as well as the importance of individualising treatment decisions, as there is often no standard therapy for patients with NETs. Finally, they look at some of the studies reporting patient preferences, and how the data can be used to inform patient decisions. 

Prefer to watch and listen? 
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/?media=1 

Watch the full video on YouTube https://youtu.be/2JYuPhc2jHg 

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution.  This podcast is supported by an Independent Medical Education Grant from Ipsen 

This podcast is developed by cor2ed.com 

Published July 2024 

The speakers share their real-life experiences of what makes a good consultation, from the perspectives of both a patient and a physician. They also explore the importance of support networks, individualising treatment, and the impact of NET and NET treatment options in daily life.  

NETs are complex, rare diseases. Optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. Are you aware of how healthcare practitioners and patients can share decision- making? Or the recent data on how patients prefer to receive treatment?  

In this first episode of a two-part podcast series, Dr Mohid S Khan and NET patient Sally Jenkins discuss shared decision-making in NET consultations and ways to help the patient in their journey. 

Prefer to watch and listen? 
Watch the video and download the full transcript on the COR2ED website https://cor2ed.com/net-connect/programmes/net-shared-decision-making/

Watch the full video on YouTube https://youtu.be/YgqrEnSePWg

Watch the highlights video on YouTube – https://www.youtube.com/watch?v=pPMVLjPLv8k

Follow us on social media 

LinkedIn: https://www.linkedin.com/company/cor2ed-net-connect  

X: https://x.com/net_connectinfo  

This content is intended for healthcare professionals only. 

The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen 

This podcast is developed by cor2ed.com 

Published July 2024 

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. 

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-2/  

Or go to the video on YouTube: https://youtu.be/zd_JvUmIhFg 

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/  

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. 

This podcast is developed by cor2ed.com

NETs are complex, rare diseases. Their optimal management and treatment requires early diagnosis, shared decision-making, and timely referral. The best possible patient journey is impacted by regional differences in management strategies, referral pathways, and availability of diagnostic modalities and treatments.. Are you aware of the epidemiology of NETs and current best practices for diagnosis, referral strategies, and treatment for NETs? Or how regional differences can impact these? In this first episode of a two-part podcast series, Prof. Martyn Caplin and Prof. Rachel Riechelmann discuss regional differences in NET epidemiology, patient pathways, as well as look to future developments.  

Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, UK, he also leads The Royal Free London “European Neuroendocrine Tumour Society’s Centre of Excellence” and the UCL Academic Neuroendocrine Tumour Unit, which includes leading scientific and clinical research programmes into NETs. Prof. Rachel Riechelmann is a medical oncologist and clinical scientist focused on colorectal/anal cancers and NETs. Director of the Clinical Oncology Department, AC Camargo Cancer Center, in Sao Paulo, Brazil and is Head of the Neuroendocrine Tumors Reference Center. 

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/net-connect/programmes/regional-differences-neuroendocrine-tumours-nets-1/  

Or go to the video on YouTube: https://youtu.be/6fKAxS4u-2o 

We are pleased to share that this podcast is endorsed by the North American Neuroendocrine Tumor Society (NANETS). You can find out more about NANETS at https://nanets.net/  

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Ipsen. 

This podcast is developed by cor2ed.com 

They discuss the different methods of communication required to build trust in patients from specific ethnic groups (African American, Hispanic and Asian American).  They also talk about the unique challenges experienced by younger patients with colorectal cancer.  Throughout the podcast the experts emphasise the importance of screening to facilitate early diagnosis and treatment.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/patient-populations-colorectal-cancer/

Or go to the video on YouTube: https://youtu.be/o-lr54-D9_g

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com

In this podcast, GI oncologists Prof. Tanios Bekaii-Saab and Prof. Shubham Pant discuss how to interpret real-world evidence in later line metastatic colorectal cancer.  They also discuss data from ASCO GI 2024 and how these results can be used to inform treatment decisions. 

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/gi-connect/programmes/real-world-evidence-mcrc/

Or go to the video on YouTube: https://youtu.be/knQcsWVqcSA

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. 

This educational podcast is developed by cor2ed.com 

Usted está viendo el tercer episodio de una serie de podcast de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.

En este episodio, escuchará a la profesora adjunta Martina Murphy (médica oncóloga) y a la profesora adjunta Caterina Marchiò (anatomopatóloga) hablar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de ovario.

A medida que se desarrolla la conversación, las expertas explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de ovario y hablan sobre los mejores métodos para minimizar las dificultades preanalíticas.

¿Prefiere ver el video mientras escucha?

Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/

O acceda al video en YouTube: https://youtu.be/HnYacC0wZp0

Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.

Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este podcast fue creado por cor2ed.com

Você está assistindo à parte 3 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá a Professora Adjunta Martina Murphy (oncologista) e a Professora Adjunta Caterina Marchiò (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de ovário.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de ovário e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-ovario-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/tiUgtzqMD-Q

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

Está escuchando la parte 1 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.

En este episodio, escuchará al especialista en genómica del cáncer genitourinario, el Dr. Alexander Wyatt, y al oncólogo médico, el Dr. Petros Grivas, profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores en el cáncer de próstata.

A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de próstata y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas.

¿Prefiere ver el video mientras escucha?

Vea el video de la conversación de los expertos y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/

O acceda al video en YouTube: https://youtu.be/WR9pX3kNao0

Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP) y de la Asociación Nacional de Coaliciones de Cáncer de Próstata (NASPCC). Puede obtener más información sobre la AMP en https://amp.org y la NASPCC en https://naspcc.org.

Los expertos médicos en este podcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics.

Este pódcast fue creado por cor2ed.com

Você está ouvindo a parte 1 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá o especialista em genoma do câncer geniturinário, Dr. Alexander Wyatt, e o oncologista, Dr. Petros Grivas, esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de próstata.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de próstata e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-prostata-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/Pp-2qMSaOPU

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP) e da Aliança Nacional das Coalizões Estaduais de Câncer de Próstata (NASPCC). Saiba mais sobre a AMP em https://amp.org e sobre a NASPCC em https://naspcc.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics.

Este podcast é desenvolvido pela cor2ed.com

Está viendo la parte 2 de una serie de podcast en video de 3 partes moderado por los Oncology Brothers, los Dres. Rohit y Rahul Gosain, especialistas en oncología y hematología.

En este episodio, escuchará a la Dra. Bruna Pellini (médica oncóloga) y al Dr. Semir Vranić (anatomopatólogo) profundizar sobre las dificultades en la fase preanalítica y las pruebas de biomarcadores del cáncer de pulmón.

A medida que se desarrolla la conversación, los expertos explican por qué es tan importante identificar las alteraciones genéticas en el cáncer de pulmón y hablan sobre los mejores métodos prácticos que contribuyen a minimizar las dificultades preanalíticas.

¿Prefiere ver el video mientras escucha?

Vea el video de la conversación de los especialistas y descargue la transcripción completa en el sitio web de COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmon-dificultades-en-la-fase-preanalitica-y-pruebas-de-biomarcadores/

O acceda al video en YouTube: https://youtu.be/LSyhFcVatSI

Nos complace compartir que este pódcast cuenta con el apoyo de la Asociación para la Patología Molecular (AMP). Puede obtener más información sobre la AMP en www.amp.org.

Los expertos médicos en este pódcast expresan sus propias opiniones y no las de COR2ED, sus colaboradores ni su institución. Este pódcast cuenta con el apoyo de una subvención educativa médica independiente de AstraZeneca y Amoy Diagnostics. Este pódcast fue creado por cor2ed.com

Você está assistindo à parte 2 da série de podcasts em vídeo de 3 partes moderados por oncologistas/hematologistas em plena atividade, os Oncology Brothers, os Drs. Rohit e Rahul Gosain.

Neste episódio, você ouvirá a Dra. Bruna Pellini (oncologista) e Semir Vranić (patologista) esclarecerem quais são os desafios da fase pré-analítica e do teste de biomarcadores para câncer de pulmão.

Ao longo da conversa, os especialistas explicam o porquê é tão importante identificar alterações genéticas no câncer de pulmão e conversam sobre as melhores práticas de abordagem que auxiliam na diminuição dos desafios na fase pré-analítica.

Prefere assistir enquanto escuta?

Assista ao vídeo da conversa dos especialistas e baixe a transcrição completa no site da COR2ED: https://cor2ed.com/precision-oncology-connect/programmes/cancer-de-pulmao-desafios-da-fase-pre-analitica-e-teste-de-biomarcadores/

Ou veja o vídeo no YouTube: https://youtu.be/lmwt0UVitF4

Temos o prazer de compartilhar que este podcast tem o endosso da Associação pela Patologia Molecular (AMP). Saiba mais sobre a AMP em www.amp.org

Neste podcast, os médicos especialistas expressam suas visões e não as da COR2ED, seus financiadores nem suas instituições. Este podcast é financiado por uma Bolsa Médica Educacional Independente concedida pela AstraZeneca e Amoy Diagnostics. Este podcast é desenvolvido pela cor2ed.com

Medical oncologists Assoc. Prof. Gerald Prager (Austria) and Dr Victor Hugo Fonseca de Jesus draw from their own clinical expertise and data from clinical trials to provide their perspectives on these questions.  They discuss how to manage side effects from available treatments to maximise survival benefit whilst maintaining quality of life and consider what the future holds for later-line treatment in metastatic colorectal cancer.

Prefer to watch as well as listen?

Watch a video

of the experts in conversation and download the full transcript on the COR2ED

website: https://cor2ed.com/gi-connect/programmes/patient-outcomes-mcrc/

Or go to the video on YouTube: https://youtu.be/ftjskGynDIc

We are pleased to share that this podcast is endorsed by Bayer

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer.

This educational podcast is developed by cor2ed.com

In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close collaboration with the pathologist and other members of the multidisciplinary team for optimal patient care.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website:https://cor2ed.com/precision-oncology-connect/programmes/precision-oncology-nsclc/

Or go to the video on YouTube: https://youtu.be/Gn_sjyexreM

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com

You are watching part 3 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode, you’ll hear Assoc. Prof. Martina Murphy (medical oncologist) and Assoc. Prof. Caterina Marchiò (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in ovarian cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in ovarian cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/ovarian-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://youtu.be/EabQZ4CKf5s

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

You are watching part 2 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs Rohit and Rahul Gosain.

In this episode, you’ll hear Dr Bruna Pellini (medical oncologist) and Semir Vranić (pathologist) shine a spotlight on the pre-analytical phase challenges and biomarker testing in lung cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in lung cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen? 

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/lung-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://youtu.be/OG7pWLZ5KMk

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP). You can find out more about AMP at www.amp.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics. This podcast is developed by cor2ed.com.

In this podcast, gastrointestinal oncologists Dr Thomas Winder (Austria and Switzerland) and Dr Mark Lewis (USA) discuss the treatment of metastatic colorectal cancer, third line and beyond.  They discuss the sequence of later line treatments regorafenib, TAS-102, bevacizumab and fruquintinib and refer to key clinical trials such as SUNLIGHT, CORRECT, RECOURSE, FRESCO-2 and ReDOS.  They emphasise the importance of balancing treatment efficacy whilst considering adverse event profiles to maintain the patient’s quality of life. 

The experts also discuss biomarkers used in a number of molecularly selected trials such as HER2 in the HERACLES (trastuzumab plus lapatininb), MOUNTAINEER (tucatinib plus trastuzumab) and DESTINY-CRC02 (trastuzumab deruxtecan) studies and KRAS G12c in the CODEBREAK 300 study (sotorasib plus panitumumab).

Join Prof. David Hong (Medical Oncologist at MD Anderson Cancer Center, Houston, Texas, United States) and Dr Tracy L Stockley (Pathologist and Geneticist at University Health Network, Toronto, Canada) as they deep dive into the topic of tumour agnostic therapies in this video podcast.

As the conversation unfolds, the precision oncology experts explore the issues and challenges associated with developing tumour agnostic therapies and discuss how these treatments differ from others.

Listen to deepen your understanding of:

• Biomarker targets associated with tumour agnostic therapies
• Which tumours carry these gene alterations
• Appropriate genetic testing strategies to detect these biomarkers

 Prefer to watch as well as listen?

Watch a video of the experts in conversation and get the clinical takeaways and podcast transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/tumour-agnostic-therapies/

Or go to the video on YouTube: https://www.youtube.com/watch?v=AO33Yv0RTVs

Find out more about the experts Prof. David Hong and Dr Tracy L Stockley

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer and is developed by cor2ed.com.

You are listening to part 1 of a 3-part video podcast series moderated by active, practising oncologists/hematologists, the Oncology Brothers, Drs. Rohit and Rahul Gosain.

In this episode, you’ll hear GU cancer genomics expert Dr Alexander Wyatt and medical oncologist Dr Petros Grivas shine a spotlight on the pre-analytical phase challenges and biomarker testing in prostate cancer.

As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in prostate cancer and discuss best practice approaches to help minimise pre-analytical challenges.

Prefer to watch as well as listen?

Watch a video of the experts in conversation and download the full transcript on the COR2ED website: https://cor2ed.com/precision-oncology-connect/programmes/prostate-cancer-preanalytical-challenges-biomarker/

Or go to the video on YouTube: https://www.youtube.com/watch?v=Sxzw1SX3nao

We are pleased to share that this podcast is endorsed by the Association for Molecular Pathology (AMP) and The National Alliance of State Prostate Cancer Coalitions (NASPCC). You can find out more about AMP at https://amp.org and NASPCC at https://naspcc.org

The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from AstraZeneca and Amoy Diagnostics.

This podcast is developed by cor2ed.com.

Experts discuss what causes PPH and how to determine the risk before and during labour with algorithms and other helpful tools. The discussion moves to when haematologic expertise is required and how collaboration can be optimized to provide the best care for patients. Furthermore, the experts share their learnings from clinical practice through discussion of specific patient cases, including patients with and without underlying bleeding disorders, as well as where haemostatic agents fit in the protocol.

Experts discuss how different tumours affect the risk for thrombosis in patients and genetic disorders such as thrombophilia. They cover multiple scores (Khorana, Vienna, PROTECHT and Pabinger) that might help to categorise thrombosis risk in oncology patients.

The discussion moves to how cancer patients with thrombosis should be treated and the duration of treatment of low molecular weight heparins and direct oral anticoagulants (DOACs), with reference to the CLOT study and recent guidelines. In addition, they discuss whether there should be a different approach with hospital in- and out-patients

 Finally, both experts discuss anticoagulation and oncocardiology and the higher incidences of atrial fibrillation reported in cancer patients.

In this podcast, the experts give an overview of the current 1^st and 2^nd line systemic treatment options and sequences for patients with advanced HCC by looking into the results from different clinical trials and current guidelines. They also shine a light on the differences in approved 2^nd line systemic therapies between Europe and USA.

The experts present their approach in making the decision to switch to 2^nd line therapy, thereby taking toxicity, liver function and disease progression into account. They also discuss the need for comparative effectiveness data to determine the optimal 2^nd line therapy.

This podcast is a conversation between two independent experts: Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai.

The experts discuss genetic testing and why identifying genetic alterations is a critical step to achieving optimal patient care. They share their multidisciplinary perspectives on when to use molecular profiling and which testing methodologies should be used to identify genetic alterations to inform treatment decisions with targeted therapies throughout the patient journey.

Dr. Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr. Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai discuss oral SERDs, a novel therapy for ER+/HER2- advanced or metastatic breast cancer.

In the second episode, Dr Klempner presents a case of a patient with advanced/metastatic gastric cancer.  The two experts discuss biomarker testing such as MMR, HER2, PD-1 and CLDN 18.2. They also discuss treatment options, CPS scoring and test selection plus recent clinical trial data that are practice changing.

In this first episode, Dr Smyth presents a case of operable localised gastric cancer.  The two experts discuss the importance of MMR biomarker testing And CROSS VS FLOT management approaches. They refer to data from recent clinical trials in upper gastrointestinal cancer such as MATTERHORN, NEONIPIGA, INFINITY, KEYNOTE-811 and KEYNOTE-585 and how data might impact clinical management. 

Dr.Rena Callahan an Associate Clinical Professor of Hematology Oncology at University of California, Los Angeles David Geffen School of Medicine and Dr.Shaheenah Dawood, a consultant medical oncologist and professor of oncology at Mediclinic City Hospital, United Arab Emirates, Dubai explore new endocrine therapies for ER+/HER2- advanced or metastatic breast cancer. More specifically, they discuss  oral SERDs efficacy and safety profile as well as their place in treatment landscape 

 The experts discuss key data from the PEACE 1 and ARASENS trials of triplet therapy with abiraterone and darolutamide respectively, in combination with ADT and docetaxel. They discuss the importance of the nurse role in communicating and educating the patient about the benefits and risks of different triplet regimens.

 They debate whether triplet therapy should be the new standard of care for all mCSPC patients and discuss the patient subgroups that benefit the most from early treatment intensification.

 The experts discuss the treatments currently approved at third line – regorafenib and TAS-102 (trifluridine/tipiracil).  They also reflect on data presented at ASCO GI 2023 from the SUNLIGHT trial which studied the use of TAS-102 plus bevacizumab as third-line treatment in refractory colorectal cancer and where this treatment may fit into the treatment sequence in the future.  They also look at data from the FRESCO-2 trial which was presented at ESMO 2022 and studied fruquintinib in the later line mCRC setting..  The discussion then moves to treatments for molecularly selected mCRC patients with the MOUNTAINEER trial where a combination of trastuzumab and tucatinib was studied.  Finally, they discuss EGFR rechallenge and data from the CRICKET and CHRONOS trials. 

The experts discuss how to apply key data from the PEACE 1 and ARASENS trials of triplet therapy with abirateroneand darolutamide respectively, in combination with ADT and docetaxel into their clinical practice. They debate whether triplet therapy should be the new standard of care for all patients and discuss the patient subgroups that benefit the most from early treatment intensification.

A number of patient scenarios are considered alongside the efficacy of the novel hormonal combinations, adverse event profiles, drug to drug interactions, volume of disease, age, comorbidities and patient risk.

In this podcast, the experts discuss the updated survival analysis from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and the second interim analysis from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in mCRPC patients with homologous recombination repair alterations. They also discuss the differing trial results and how these compare to the most recent data presented from the TALAPRO-2 trial of talazoparib plus enzalutamide which showed a benefit in a biomarker unselected population.

The experts consider how this combination therapy may be implemented in clinical practice in the future pending regulatory approval of the combinations.

In this podcast, the experts give an overview of the current systemic treatment options for patients by looking into the results from different clinical trials and current guidelines, as the field is rapidly evolving since 2017. They discuss the patient cohorts who are not eligible for IO in first line, such as patients with underlying auto-immunity, impaired organ function and patients who decline IO.

The experts discuss the efficacy and safety data from the SHARP and Asia Pacific trials of sorafenib and from the REFLECT trial of lenvatinib, which are both tyrosine kinase inhibitors (TKIs) and available for the aforementioned patient cohorts. They also present their approach to toxicity management for patients receiving those TKIs.

In this podcast, the experts discuss efficacy and safety data from the PROPEL study of olaparib and abiraterone which demonstrated a benefit in an all-comer mCRPC population and data from the MAGNITUDE study which showed a benefit of niraparib plus abiraterone in a biomarker positive mCRPC population. The experts discuss the differing trial results and how these compare to the TALAPRO-2 trial of talazoparib plus enzalutamide.

They discuss the value of genetic testing considering these results and debate whether an all-comer mCRPC patient population should be treated with a PARP inhibitor plus NHA combination or whether treatment should be determined based on HRR alterations. 

The experts consider how this combination therapy may be implemented in clinical practice in the future including how to manage patients who are already receiving a NHA prior to becoming castration resistant.

In this podcast, the experts discuss the key efficacy and safety findings from the olaparib registration study, PROfound, and the TRITON-2 study which led to accelerated approval for rucaparib. They also discuss the recent data from the rucaparib confirmatory phase 3 trial, TRITON 3 and based on the results of these studies, debate are all PARP inhibitors the same and can the results be extrapolated from one PARP inhibitor to another.

The timing of treatment with PARP inhibitors versus taxanes is also explored.

Genetic testing is amongst the topics covered, including when to consider germline versus somatic testing and the impact of various homologous recombination repair alterations on efficacy.

The experts start by discussing the SUNLIGHT trial which studied the use of trifluridine/tipiracil plus bevacizumab as third-line treatment in refractory colorectal cancer.  The discussion then moves on to a trial which evaluated the kinetics of post operative circulating cell-free DNA and its impact on minimal residual cell detection in patients with stage I-III colorectal cancer. 

The third abstract the experts discussed was a phase I trial which study botensilimab plus balstilimab in MSS colorectal cancer patients. Finally they discuss the long term results of NRG-GI002, a phase 2 trial which looked at the use of total neoadjuvant therapy in locally advanced rectal cancer. 

 The experts start by covering a number of metastatic studies.  First of all, they discuss SPOTLIGHT, a study which investigated the novel agent zolbetuximab as first line treatment in patients with claudin-18.2+/HER2 locally advanced unresectable or metastatic gastroesophageal cancer.  Next they discuss Rationale 305, a study that looked at the activity of tislelizumab in combination with chemotherapy versus chemotherapy alone in patients with PD-L1 positive tumours.  They also discussed the three-year follow up results from CheckMate 649, looking at nivolumab plus chemotherapy vs chemotherapy alone as first-line treatment for advanced gastroesophageal cancer.  The discussion then moves on to INTEGRATE IIa, a study comparing regorafenib with placebo in refractory advanced gastroesophageal cancer. 

Prof. Jonathan Trent is Associate Director for Clinical Research, the Director of the Bone and Soft-tissue Sarcoma Group and Medical Director of the Precision Medicine Initiative at the Sylvester Comprehensive Cancer Center in the University of Miami Health System, Miami, FL, USA. Prof. Robin Jones is Head of the Sarcoma Unit at The Royal Marsden NHS Foundation Trust, London, UK.

In this podcast, the two experts discuss data from key trials CHECKMATE 214 (ipilimumab and nivolumab), KEYNOTE 426 (axitinib and pembrolizumab), CHECKMATE 9ER (cabozantinib and nivolumab), CLEAR (Lenvatinib and pembrolizumab) and COSMIC 313 (cabozantinib plus nivolumab and ipilimumab) and the implications for clinical practice.

They also discuss management of toxicities associated with combination treatments, including dosing strategies to ensure the patient remains on optimal treatment and improved education for patients and clinicians so that they recognise side effects and how to manage them.

They share their clinical experience and their own clinical practice, based on data from key studies including NETTER-1, CLARINET FORTE, and REMINET, as well as relevant retrospective analyses. Prof. Martyn Caplin is Professor of Gastroenterology and GI Neuroendocrinology at the Royal Free Hospital and University College London, London, UK. Dr Aman Chauhan is a Medical Oncologist and Director of NET Theranostics at the University of Kentucky Markey Cancer Center, Kentucky, USA.

The experts start by covering a number of first line studies. First of all, they discuss a study from Dr. Janjigian’s research group which investigated regorafenib with nivolumab and FOLFOX in HER2 negative oesophagastric cancer.  They then discuss LEAP-015 which investigated first-line lenvatinib plus pembrolizumab plus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (GEA).  Dr. Klempner then covers one of his posters from ESMO 2022 on the DisTinGuish trial which looked at DKN-01 and tislelizumab plus chemotherapy as first-line investigational therapy in GEA.  Later they discuss MOONLIGHT which investigated FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.  Later in the podcast, they cover a number of second line studies, including the PRODIGE 59 - DURIGAST trial which evaluated FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second line treatment of patients with advanced gastric or GEJ adenocarcinoma.  Finally they discuss DESTINY-Gastric02 which followed on from DESTINY-Gastric01 in Asian patients and was undertaken to evaluate T-DXd in Western patients with HER2+ unresectable/metastatic gastric/GEJ cancer who progressed on or after trastuzumab-containing regimen.

They start their discussion with the  NICHE-2 which looked at neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer. Discussion then moves to the HIPECT4 trial which explored adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer and challenges previous perceptions of HIPEC in colorectal cancer patients. The FRESCO-2 trial is reviewed which evaluated the efficacy and safety of fruquintinib in patients with refractory metastatic CRC with results potentially supporting a new option for these patients. The experts then review two trials in patients with KRASG12C mutant CRC, the KRYSTAL-1 which used adagrasib with or without cetuximab in these patients and the CodeBreaK101 study which used sotorasib in combination with panitumumab.  They discuss their opinions on the results from these studies and the implications for clinical practice.

Sven De Keersmaecker RN is Study Co-ordinator at Antwerp University Hospital in Belgium and Dr Gerald Prager is a Medical Oncologist and Associate Professor at Medical University of Vienna in Austria.

Prof. Amit Singal is Director of Liver Cancer Program at UT Southwestern Medical Center, Dallas, TX, USA and Assoc. Prof. Neil Mehta is Director of Liver Cancer Program at University of California San Francisco, USA.

The experts discuss:

• Treatment intensification with triplet therapy for mCSPC patients with practice changing data from the ARASENS trial and updated overall survival from the ENZAMET trial
• Subgroup analysis of prior and concomitant treatment from the VISION trial
• A number of practice development studies using technology to aid knowledge sharing and to improve the quality of patients’ care

In this podcast, the experts discuss how patients are more likely to be able to adhere to a treatment plan if they understand their choices and the implications of each treatment. 

They discuss how nmCRPC patients are relatively asymptomatic and the importance of understanding the patients’ goals of treatment and how these may differ from a physician’s perspective.

Alicia reviews the efficacy and safety data from the key trials for nmCRPC, the SPARTAN trial with apalutamide, the PROSPER trial with enzalutamide and the ARAMIS trial with darolutamide.

Brenda discusses ways to manage adverse events for the nmCRPC patients in order to keep them on treatment whilst still maintaining a good quality of life and Alicia explains how she goes about determining the right treatment for the right patient whilst considering comorbidities and drug to drug interactions.

In this podcast, the experts reflect on how the treatment landscape for mCSPC has evolved over the past 7 years resulting in treatment intensification with ADT plus docetaxel following the CHAARTED and STAMPEDE studies and then more recently the use of ADT and androgen receptor inhibitors including abiraterone (LATITUDE, STAMPEDE), apalutamide (TITAN), and enzalutamide (ARCHES, ENZAMET). 

This has further evolved with the recent reporting of the PEACE 1 and ARASENS trials which demonstrated a survival benefit with triplet therapy with abiraterone and darolutamide respectively, being used in combination with ADT and docetaxel.

The experts discuss the importance of balancing benefit against risk for their mCSPC patients but state that the triplet therapies appear to be well tolerated in both the PEACE 1 and ARASENS trials.

They provide their views, Neal as a urologist and Tanya as a medical oncologist, on the things to consider when making treatment decisions for these patients such as comorbidities, age, performance status, de novo versus recurrent disease, amongst others.

They finish by concluding that treatment intensification should be implemented as standard of care for mCSPC patients to enable patients to have as many treatments with different mechanisms of action as early as possible in their treatment journey. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

In this podcast, the experts review data from a number of key plenary sessions from ASCO GU 2022 and discuss potential implications for clinical practice. The ARASENS trial is covered first which looked at triplet therapy in the form of ADT plus docetaxel and darolutamide in patients with metastatic castration sensitive prostate cancer (mCSPC). Discussion then moves to two trials investigating the combination of abiraterone acetate with PARP inhibitors in metastatic castration resistant prostate cancer (mCRPC) patients with and without homologous recombination repair (HRR) mutations: the PROpel trial with olaparib and the MAGNITUDE trial with rucaparib. 

Neal and Alicia also discuss a fascinating presentation by Dr. Daniel Spratt which looked at digitising histopathology slides and using Artificial Intelligence (AI) to inform on the likelihood of disease progression and whether or not patients needed androgen deprivation therapy (ADT)

Finally, Alicia discusses a number of posters which she felt made an impact, including one on PSA responses in the TITAN and SPARTAN trials and a secondary analysis from the VISION trial looking at treatment related adverse events, amongst others. 

In this podcast, the experts discuss adverse events associated with PARP inhibitors and the management of them, in particular thrombocytopenia, gastrointestinal effects and fatigue. Jason provides some insight into how nurses support and communicate with patients, the importance of early reporting of side effects and how to manage these. Finally, the ongoing trials of PARP inhibitors in combination with other prostate cancer treatments are also considered and what these trials may mean for patients.

En este podcast, los expertos analizan los inhibidores de PARP (PARPi), cómo funcionan y los datos clave de los ensayos de registro de rucaparib y olaparib, TRITON2 y PROfound. También discuten cómo seleccionar PARPi para sus pacientes con cáncer de próstata y dónde encajan en la secuencia general del tratamiento. Pablo brinda información sobre la comunicación con los pacientes y los tipos de preguntas e inquietudes que suelen tener en relación con las pruebas genéticas y el tratamiento con PARPi. Además, también analizan los PARPi que se encuentran actualmente en la última etapa de desarrollo, como niraparib y talazoparib, así como el posible uso futuro de los PARPi en combinación con inmunoterapias o inhibidores de la vía del receptor de andrógenos.

In this podcast, the experts discuss PARP inhibitors (PARPi’s), how they work and key data from the registration trials for rucaparib and olaparib, TRITON2 and PROfound.  They also discuss how to select PARPi’s for their prostate cancer patients and where they fit in the overall treatment sequence. Pablo provides some insight into communicating with patients, and the types of questions and concerns they often have in relation to genetic testing and treatment with PARPi’s.  In addition, they also discuss the PARPi’s currently in late-stage development such as niraparib and talazoparib as well as the potential future use of PARPi’s in combination with immunotherapies or androgen receptor pathway inhibitors.

In this podcast, the experts discuss the gene alterations in prostate cancer and why we should consider genetic testing when thinking about treatment options such as PARP inhibitors (PARPi’s). The discussion covers why genetic testing should be performed, who should undergo testing, how to test and what this means in relation to treatment with PARP inhibitors. Dr. Alex Wyatt explains the difference between germline and somatic mutations and Joanne Chien discusses the role of the nurse during genetic counselling discussions and how this role may evolve in the future. Finally, the ongoing trials of PARP inhibitors in combination with other prostate cancer treatments are also considered and whether the outcome of these trials is likely to impact the need to perform genetic testing.

They discuss a number of techniques and strategies to identify this rare fusion in lung cancer patients, before going on to summarise the robust efficacy and safety data for both entrectinib and larotrectinib. Prof. Rolfo briefly covers second-generation therapies in clinical development and describes how liquid biopsy is emerging as a new technique not only to identify but also monitor patients. They conclude by stressing the importance of the collaboration and communication between pathologists and oncologists to test for and identify TRK fusion-positive lung cancer patients.

Combination approach has been validated recently with the atezolizumab+bevacizumab combination being the new standard of care in 1L setting for advanced HCC patients. In the context of advanced HCC, both experts share their view about the dosing approach with VEGFR-TKI and provide insight to handle the dosing when combining with PD-1 inhibitor.

Both experts reiterate that biomarkers are urgently needed in HCC and summarize the current stratification of patients used to predict the response with VEGFR-TKI monotherapy or in immunotherapy combination. Finally, they emphasize that pre-habilitation of HCC patients is key to make the HCC patient fit for the best available treatment option.

In this podcast, by COR2ED Medical Education, the two experts discuss key trials (CHECKMATE 214, KEYNOTE 426, CHECKMATE 9ER and CLEAR) which have led to recent updates to the ESMO and EAU treatment guidelines for RCC. Combination treatment with either VEGFR targeted therapy plus a PD-1 or CTLA-4 inhibitor in the first-line setting is discussed as well as VEGFR-TKI monotherapy options at the time of disease progression.

They also focus on how to manage treatment toxicity whilst trying to optimise treatment outcomes and preserving patients’ quality of life as well as the use of biomarkers and risk stratification models.

In this third episode, the experts turn their focus to earlier stage disease and consider how lessons learnt in the treatment of metastatic disease can be applied in the neo adjuvant setting for colorectal cancer by discussing data from the FOXTROT and NICHE trials and the adjuvant setting for gastric cancer by discussing data from CheckMate 577. Finally, the experts consider new promising data on targeting KRAS compared to the MEK and the ERK inhibitors.

This second episode focuses on recent developments in immunotherapy approaches in metastatic colorectal and gastric cancer – specifically whether immunotherapy should be used alone, in combination with other treatments or with chemotherapy. Data from several clinical trials are discussed such as KEYNOTE-177, CheckMate 142, CheckMate 649, KEYNOTE 062, and NICHE. The experts also consider the appropriate treatment regimens for MSI-high and MSS colorectal and gastric cancer patients and whether CPS is an appropriate biomarker for gastric cancer.

In this first episode the experts discuss novel targeted approaches in metastatic colorectal and gastric cancer. They discuss practice changing drug targets including BRAF and HER2 with reference to data from recent clinical trials such as DESTINY and HERACLES. They also discuss molecular testing and differences in approaches between the USA and Europe and review recommendations in the guidelines for colorectal and gastric cancer.

In this second episode, Dr. Richter and Dr. Ramasamy explore how to select the best treatment approach in the second-line setting and beyond. Firstly, they discuss at what point they consider a patient to actually be in relapse. They both believe that it’s important to stay on top of this incurable illness and act when there is a suspicion of relapse. However, the need to treat must be balanced with quality of life. They also take potential enrolment into a clinical trial into account in the treatment decision.

The decision on which treatment option to select in the second line and beyond mostly depends on refractoriness to other drugs. With an increasing number of novel treatment options becoming available, choosing a regimen that does not contain a drug the patient is refractory to is becoming easier. Dr. Richter and Dr. Ramasamy discuss the challenges around these treatment decisions.

Furthermore, they share their experiences with CAR-T and other T cell redirection therapies, and when to use it in the treatment sequence. The speakers conclude with a look into the future of myeloma treatment.

In this first episode, Dr. Richter and Dr. Ramasamy discuss how to select the best approach in newly diagnosed patients with multiple myeloma. The experts look at transplant eligibility as one of the key factors in deciding which treatment to start with in the front-line setting. They discuss the potential for personalising therapy in newly diagnosed patients, both in the transplant setting as well as in patients who are not eligible for transplantation.

They also comment on the impact of MRD negativity in clinical practice and agree that the goal of treatment is to induce deep remissions. However, which patient needs triple or quadruplet therapy to achieve this goal is still unclear and the risk-benefit profile needs to be considered for each individual patient.

The final topic that the experts share their points of view on is continuous vs fixed-duration maintenance therapy.

One main topic included discussions about treatment options in first-line systemic therapy and managing patients who still may need to receive a TKI in first-line instead. Another topic covered is how to proceed with immunotherapy in HCC, in particular the rationale for triplet immunotherapy combination.

There were two studies data presented on atezolizumab plus bevacizumab, the new reference standard of care in systemic front-line HCC treatment.

Another interesting topic was the combination of TACE with immune checkpoint blockade in intermediate stage HCC.

Regarding monotherapy TKI in first-line setting, Prof Pinter points out that around 15 to 20% of HCC patients are not ideal candidates for atezolizumab plus bevacizumab, and these are mainly patients with HCC recurrence of the liver transplantations, patients with severe autoimmune disease, or those with a high bleeding risk.

He discusses several real-world evidence studies including lenvatinib, sorafenib and regorafenib in special populations that are usually excluded from clinical trials.

 Prof Pinter also discusses data presented covering predictive and prognostic biomarkers such as cachexia, the growing role of AI, multibipolar radiofrequency ablation and the potential role of underlying etiology as a predictor of the efficacy of immunotherapy.

Penault-Llorca and Sartore-Bianchi start by explaining TRK fusion biology, the role as oncogenic drivers and briefly describe the two approved TRK inhibitors. They then discuss the challenges of finding patients harboring these fusions, referring to how enrichment strategies and predictors can aid identification in patients with GI cancers. Finally, they discuss key efficacy and safety data for larotrectinib and entrectinib, as well as mentioning second-generation products in development to tackle mechanisms of resistance.

VEGFR-TKIs are widely used treatments for these solid tumours but are associated with substantial toxicity which needs early recognition and management in order to help patients stay on optimal treatment.

The most common adverse events related to these treatments are discussed together with recommendations for their management. Veerle and Paola discuss the key role of the nurse as part of the multi-disciplinary team involved in the patient’s care, and the role they have in providing close support and guidance to the patient. Education of patients regarding potential side effects and early identification and management of adverse events is key in terms of trying to keep patients on the optimum dose so that they can achieve the best outcomes.

In this podcast, the two experts discuss key trials (SELECT, DECISION and COSMIC-311) and efficacy parameters of the current VEGFR-TKIs (lenvatinib, sorafenib and cabozantinib), how to manage toxicity whilst trying to optimise treatment outcomes and preserving always patients’ quality of life. They also discuss treatment strategies, when to start systemic treatment, which drug should be used first and how to sequence therapies. To close the podcast they take a look at ongoing clinical trials with other treatments in development for DTC.

Dr Choo comments that despite the promising and positive data with hepatic arterial infusion chemotherapy (HAIC) in two different Phase 3 trials settings, the impact on clinical practice is still questionable.

Dr Choo reviews some updated data from IMbrave150 which is the study that validated atezolizumab+bevacizumab combination as the new standard of care in 1L setting for aHCC patients. In addition, real-world data from OPTIMIS and GIDEON studies, confirmed that sorafenib has still a role to play in 1L specifically in Child-Pugh B patients.

Dr Choo emphasises that biomarkers are urgently needed in HCC and summarises several studies investigating potential biomarkers that would require further investigation prior to clinical practice validation.

Finally, Dr Choo completes the overview by presenting a Japanese study that provides support for radio frequency ablation as an option, apart from surgery for patients with small HCC.

This second episode focuses on PSMA-targeted radiopharmaceuticals and how PSMA can be a target for imaging as well as for therapies. Efficacy and safety data from the phase 2 TheraP study are discussed which investigated lutetium-PSMA versus cabazitaxel in patients with mCRPC who had progressed on docetaxel. The experts also discuss the ongoing VISION trial and what the results may mean for clinical practice as well as other ongoing trials looking at lutetium-PSMA in combination with other prostate cancer therapies such as PARP inhibitors, immunotherapies, hormonal therapies and chemotherapy. Treatment sequencing is also considered in terms of where lutetium-PSMA fits into clinical practice for mCRPC patients and how the treatment compares to Radium-223.

In this first episode, the experts focus on the alpha emitter, Radium-223 which received regulatory approval on the basis of the phase 3 ALSYMPCA trial in patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastases. They consider mechanism of action and discuss key results from the trial and the safety profile.

The experts also review the ERA-223 and PEACE-III randomised trials which investigated the use of Radium-223 in combination with next generation androgen receptor inhibitors (ARIs). A number of real-world evidence studies are also reviewed as the experts consider where radium-223 fits into the overall treatment sequence for mCRPC patients. Radiation safety and general considerations for delivering therapy with radiopharmaceuticals are also discussed.